Consistent with our in vitro results, tumor tissue prior to ALK inhibition therapy showed negative BIM staining, whereas the histological section removed during lorlatinib treatment showed some areas with a slight increase in BIM expression, although this increment was not as high as expected (Supplementary Fig. S1). The gene discussed is BCL2L11; the disease is neoplasm.